Scarborough, NY, United States of America

Daniel Meruelo

This inventor holds 26 USPTO granted patents and 10 published patent applications, plus 7 CIPO patents and 4 EPO patents, primarily in Viral Vector Technology. Top assignees: New York University, Yeda Research and Develpment & Co. Ltd, Other. Active years: 1991-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Meruelo. Retrieved from https://idiyas.com/inventor/daniel-meruelo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 10)

% Patents Active = 84.6

CIPO Patents = 7 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 98(Granted Patents)

Company Filing History:

Yeda Research and Develpment & Co. Ltd

patents

2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2024

Loading Chart...

Areas of Expertise:

Antitumor Immunity

Viral Vectors

Cancer Detection

Sindbis Virus

Laminin Receptor

Alphavirus

Chimeric Polypeptides

Antiviral Agents

Compound Delivery

Biological Fluid Purification

Tumor Therapy

Hypericin

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116412 - Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins (2024-10-15),

2. 12097257 - Induction and enhancement of antitumor immunity involving Sindbis virus vectors expressing immune checkpoint proteins (2024-09-24),

3. 10010628 - Method for inducing antitumor immunity using Sindbis viral vectors and tumor associated antigens (2018-07-03),

4. 8530232 - Defective Sindbis viral vector comprising an anti-tumor gene (2013-09-10),

5. 8282916 - Tumor therapy with replication competent sindbis viral vectors (2012-10-09),

6. 8114961 - Human laminin receptor crystal and uses thereof (2012-02-14),

7. 8093021 - Defective sindbis viral vectors (2012-01-10),

8. 7910093 - Method for detecting cancer cells and monitoring cancer therapy (2011-03-22),

9. 7807147 - Tumor therapy with high affinity laminin receptor-targeted vectors (2010-10-05),

10. 7378272 - Packaging cell lines for the continuous production of alphavirus vectors (2008-05-27),

11. 7306792 - Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors (2007-12-11),

12. 7303898 - Defective sindbis viral vectors (2007-12-04),

13. 7071301 - Chimeric viral receptor polypeptides, human viral receptor polypeptides and uses thereof (2006-07-04),

14. 6576784 - Antiviral agents (2003-06-10),

15. 6503499 - Viral vector complexes having adapters of predefined valence (2003-01-07),

Title: **The Innovative Contributions of Daniel Meruelo**

Introduction

Daniel Meruelo, based in Scarborough, NY, has made significant contributions to the field of biotechnology and immunology, particularly in the development of novel therapeutic approaches for treating cancer. With an impressive portfolio of 26 patents to his name, Meruelo stands out as a prolific inventor in his area of expertise.

Latest Patents

Among his latest innovations, Meruelo holds patents for methods related to the induction and enhancement of antitumor immunity utilizing virus vectors. One notable patent describes polynucleotides and viral vectors, specifically alphavirus or Sindbis viral vectors, which encode multiple epitopes of at least one tumor-associated antigen. These vectors are designed to stimulate the immune system by enhancing the anti-cancer immune response, thereby improving patient survivability. Additionally, he has developed methods using Sindbis virus vectors that express immune checkpoint proteins, targeting tumors effectively and promoting significant reductions in tumor growth.

Career Highlights

Throughout his career, Daniel Meruelo has been associated with prestigious institutions such as New York University and Yeda Research and Development Company. His work in these organizations has allowed him to advance the science of immunotherapy and contribute to innovative cancer treatments that harness the body’s own immune system.

Collaborations

Meruelo has collaborated with esteemed colleagues, including Gad Lavie and Christine L Pampeno, enriching his research with diverse insights and expertise. These collaborations have played a crucial role in the development of his groundbreaking patents and innovative therapeutic strategies.

Conclusion

Through his extensive research and innovative patents, Daniel Meruelo continues to pave the way for advancements in cancer therapy. His work not only reflects his dedication as an inventor but also his commitment to improving patient outcomes through scientific innovation. The contributions of inventors like Meruelo are vital to the ongoing evolution of medical science, particularly in the fight against cancer.

Profile summary based on public USPTO records.